IPO Company Profile
SEC Filings | Peer IPO Companies
Intracel Corporation
2005 NW Sammamish Road, Suite 107, Issaquah, WA 98027 * (425) 392-2992

The company is an integrated biopharmaceutical company focused on the development and commercialization of cancer vaccines and immunotherapeutic and diagnostic products for cancers and infectious diseases.

Primary Underwriting Group
ManagerTierPhone
Donaldson, Lufkin & Jenrette Securities Corp.Lead Manager (212) 371-0641
Nationsbanc Montgomery Securities, Inc.Co-manager (415) 627-2100

Filing Information
NASNTL:ICEL Manufacturing: SIC 2834
Type of Shares:Common Shares Filing Date:7/9/98
U.S. Shares Filed:4,000,000 Filing Range:$12.00 - $14.00
Non-U.S. Shares Filed:0 Offering Amount: $52,000,000
Primary Shares:4,000,000 Expenses: -
Secondary Shares:0 Post-IPO Shares:15,400,000
Employees:240

Legal Counsel, Auditor and Registrar
Issuer's Law Firm: Morrison & Foerster
Bank's Law Firm: Brown & Wood
Auditor: Pricewaterhouse Coopers LLC

Selected Financial Data

Dollar amounts in U.S. millions except for per share data
3 Month Ending Financials
Full Year
Audited
Income
Latest
Unaudited
Income
Prior
Audited
Income
Balance
Sheet
12/31/97 3/31/98 3/31/97 3/31/98
Revenue:$13.45$5.46$3.79Assets:$45.65
Net Income:-$8.48-$42.59-$1.73Curr Assets:$8.69
EPS:Liabilities:$41.57
Prior EPS:Curr Liab:$12.87
Cash Flow/Oper:-$2.51-$2.96-$1.19Equity:$4.07
Cash Flow/Fin:$5.52-$0.05$1.56Cash:$0.73
Cash Flow/Inv:-$4.18$1.77-$0.68Working Cap:-$4.18

Use of Proceeds
The proceeds from the proposed offering will be used to support the establishment and early operation of oncoVAX Centers, to repay existing indebtedness, and for research and development, to conduct clinical trials for the company's cancer and infectious disease products and for working capital and general corporate purposes.

©1998 IPO Data Systems, Inc. - All rights reserved.